Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Fintel reports that on December 31, 2024, DA Davidson initiated coverage of Vertex (NasdaqGM:VERX) with a Buy recommendation.

Vertex, Inc. (NASDAQ: VERX) has been recognized as a Leader in three IDC MarketScape reports for 2024. The company earned ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Vertex (VERX) has received a new Buy rating, initiated by D.A. Davidson analyst, Will Jellison.Don't Miss Our New Year's Offers:Discover the ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have received a consensus rating of “Moderate Buy” from the eleven ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, ...

The french-fry maker replaced its chief executive and [slashed guidance again]( ...

Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a ...